5 Drugs Stocks On The Rise

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 147 points (1.0%) at 15,587 as of Thursday, Feb. 6, 2014, 11:55 AM ET. The NYSE advances/declines ratio sits at 2,311 issues advancing vs. 626 declining with 152 unchanged.

The Drugs industry currently sits up 0.8% versus the S&P 500, which is up 1.0%. Top gainers within the industry include Biogen Idec ( BIIB), up 1.9%, Shire ( SHPG), up 1.8%, Novo Nordisk A/S ( NVO), up 1.7%, GlaxoSmithKline ( GSK), up 0.9% and Johnson & Johnson ( JNJ), up 0.9%.

TheStreet would like to highlight 5 stocks pushing the industry higher today:

5. Novartis ( NVS) is one of the companies pushing the Drugs industry higher today. As of noon trading, Novartis is up $0.88 (1.1%) to $79.43 on average volume. Thus far, 772,926 shares of Novartis exchanged hands as compared to its average daily volume of 1.3 million shares. The stock has ranged in price between $79.25-$79.61 after having opened the day at $79.55 as compared to the previous trading day's close of $78.55.

Novartis AG engages in the research, development, manufacture, and marketing of a range of healthcare products worldwide. Novartis has a market cap of $189.7 billion and is part of the health care sector. Shares are down 2.3% year-to-date as of the close of trading on Wednesday. Currently there are 4 analysts who rate Novartis a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates Novartis as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, reasonable valuation levels, good cash flow from operations, largely solid financial position with reasonable debt levels by most measures and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Novartis Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

4. As of noon trading, Regeneron Pharmaceuticals ( REGN) is up $5.53 (2.0%) to $287.43 on light volume. Thus far, 248,616 shares of Regeneron Pharmaceuticals exchanged hands as compared to its average daily volume of 811,400 shares. The stock has ranged in price between $281.89-$287.55 after having opened the day at $281.89 as compared to the previous trading day's close of $281.90.

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions in the United States and internationally. Regeneron Pharmaceuticals has a market cap of $28.0 billion and is part of the health care sector. Shares are up 2.4% year-to-date as of the close of trading on Wednesday. Currently there are 10 analysts who rate Regeneron Pharmaceuticals a buy, no analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates Regeneron Pharmaceuticals as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and notable return on equity. However, as a counter to these strengths, we also find weaknesses including unimpressive growth in net income and feeble growth in the company's earnings per share. Get the full Regeneron Pharmaceuticals Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

3. As of noon trading, Allergan ( AGN) is up $1.61 (1.4%) to $116.81 on average volume. Thus far, 985,341 shares of Allergan exchanged hands as compared to its average daily volume of 2.3 million shares. The stock has ranged in price between $116.31-$118.50 after having opened the day at $116.98 as compared to the previous trading day's close of $115.20.

Allergan, Inc. operates as a multi-specialty healthcare company primarily in the United States, Europe, Latin America, and the Asia Pacific. Allergan has a market cap of $34.1 billion and is part of the health care sector. Shares are up 3.7% year-to-date as of the close of trading on Wednesday. Currently there are 11 analysts who rate Allergan a buy, no analysts rate it a sell, and 8 rate it a hold.

TheStreet Ratings rates Allergan as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, impressive record of earnings per share growth and increase in net income. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Allergan Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading, Amgen ( AMGN) is up $1.58 (1.4%) to $116.65 on light volume. Thus far, 788,521 shares of Amgen exchanged hands as compared to its average daily volume of 3.3 million shares. The stock has ranged in price between $115.08-$116.66 after having opened the day at $115.62 as compared to the previous trading day's close of $115.07.

Amgen Inc., a biotechnology medicines company, engages in the discovery, development, manufacture, and marketing of human therapeutic products in the areas of supportive cancer care, inflammation, nephrology, and bone diseases primarily in the United States, Europe, and Canada. Amgen has a market cap of $87.3 billion and is part of the health care sector. Shares are up 1.5% year-to-date as of the close of trading on Wednesday. Currently there are 8 analysts who rate Amgen a buy, no analysts rate it a sell, and 12 rate it a hold.

TheStreet Ratings rates Amgen as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, notable return on equity, reasonable valuation levels, solid stock price performance and impressive record of earnings per share growth. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full Amgen Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading, Celgene Corporation ( CELG) is up $0.82 (0.5%) to $151.67 on average volume. Thus far, 1.3 million shares of Celgene Corporation exchanged hands as compared to its average daily volume of 2.9 million shares. The stock has ranged in price between $149.49-$152.80 after having opened the day at $151.19 as compared to the previous trading day's close of $150.85.

Celgene Corporation discovers, develops, and commercializes therapies for cancer and immune-inflammatory related diseases in the United States and Europe. Celgene Corporation has a market cap of $62.4 billion and is part of the health care sector. Shares are down 10.7% year-to-date as of the close of trading on Wednesday. Currently there are 24 analysts who rate Celgene Corporation a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates Celgene Corporation as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, notable return on equity, reasonable valuation levels, solid stock price performance and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Celgene Corporation Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 5 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

null

More from Markets

What Market Selloff? Dow Futures Are Popping on Sunday

What Market Selloff? Dow Futures Are Popping on Sunday

Street Stats: The Mid-Term Elections May Be a Rollercoaster Ride for Investors

Street Stats: The Mid-Term Elections May Be a Rollercoaster Ride for Investors

Apple and GE Switch Roles; Musk's Super Control of Tesla Explained -- ICYMI

Apple and GE Switch Roles; Musk's Super Control of Tesla Explained -- ICYMI

Trump May Be More to Blame For Higher Oil Prices Than OPEC

Trump May Be More to Blame For Higher Oil Prices Than OPEC

Dow Falls Over 200 Points as Apple's Slump Offsets Gains in General Electric

Dow Falls Over 200 Points as Apple's Slump Offsets Gains in General Electric